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Abstract. There is a need for field-applicable markers to assess morbidity associated with intestinal schistosomiasis,
especially in the context of preventive chemotherapy in young children. We investigated whether fecal occult blood
(FOB) point-of-care tests could be used to assess intestinal pathology over a 12-month period in a cohort of 382 children
(< 5 years of age). We found a strong association between egg-patent schistosomiasis and FOB at baseline (odds ratio
[OR] = 3.1, P < 0.0001), 6 months (OR = 3.4, P < 0.0001), and 12 months (OR = 3.5, P < 0.0001), despite repeated
chemotherapy. There were tendencies for prevalence of FOB to decrease in children who became egg negative and
increase in those who became egg positive. Our results demonstrate overt disease in children less than five years of age.
We therefore propose that FOB is useful for assessing dynamics of intestinal morbidity in young children at the
community level and monitoring changes in morbidity after mass chemotherapy.
INTRODUCTION
Schistosomiasis is a neglected tropical disease caused by
trematode parasites of the genus Schistosoma. These parasites
infect some 207 million persons worldwide, particularly in
sub-Saharan Africa.1 Globally, it is estimated that schistoso-
miasis is responsible for 280,000 deaths per year and the loss
of 1.53 million disability-adjusted life years.2,3 However, this
latter figure is likely to be an underestimate because schisto-
somiasis can cause a variety of subtle and hidden morbidities
that are difficult to capture within this metric and hard to
measure directly in communities to which schistosomiasis
is endemic.
In sub-Saharan Africa, the intestinal form of schistosomia-
sis is largely attributable to Schistosoma mansoni and causes a
spectrum of pathologic changes caused by detrimental reac-
tions to eggs, produced by female worms, that have become
trapped in host tissues.2 For example, intestinal morbidity
includes diarrhea, abdominal pain, intestinal granulomas and
fibrosis, polyps and microulcerations, and colonic obstruction
in extreme cases.4–10 Perforation of the intestinal mucosa by
S. mansoni eggs and colorectal polyps can cause the release of
blood into the bowel, resulting in blood in feces and anemia if
infections are heavy.4,5
Today, mass chemotherapy using the anthelminthic drug
praziquantel (PZQ) acts as the cornerstone of all national
schistosomiasis control programs. Up until now, the main
aim of these programs has been control of morbidity associ-
ated with schistosomiasis, rather than infections per se.11 As a
consequence, school age children have been particularly
targeted for mass chemotherapy because they were believed
to have the highest infection intensities and to respond to
PZQ with greater reductions in morbidity.12 However, it is
becoming clear that younger children less than six years of
age can also be infected and treated safely with PZQ.13,14
Despite the fact that the focus of national programs is on mor-
bidity reduction, monitoring and evaluation of these programs
is largely dependent on measuring infection intensities (egg
output) as a proxy for morbidity. Thus, field-applicable mor-
bidity markers are essential for defining the initial disease bur-
den andmonitoring the impact of preventive chemotherapy.
Fecal occult blood (FOB), which refers to cryptic blood in
feces, has been used for a number of years as a marker of
intestinal pathologic changes, particularly in association with
colorectal cancer. A number of point-of-care tests have been
developed,15 and as such, they are simple to use and provide
a result in minutes. Studies in Brazil, Zimbabwe, and the
Philippines using guaiac-based methods for detection of FOB
have demonstrated a positive correlation between FOB and
intensity of S. mansoni or S. japonicum infection.16–18 More
recently, we reported a strong association between FOB (as
assessed by an antibody-based test costing approximately
$1.70 per person) and S. mansoni in baseline surveys of a
cohort of young children (age = 0.5–6 years) and their
mothers. We then proposed that FOB tests could be used for
measuring morbidity associated with intestinal schistosomia-
sis but further study of longitudinal dynamics was needed.19
To extend this line of inquiry,19 we have followed-up chil-
dren in the cohort for one year, investigating the dynamics
of FOB in the face of preventive chemotherapy. We report on
a longitudinal analysis of the use of the FOB as an epidemio-
logic marker of S. mansoni-associated bowel morbidity in
children 5 months–5 years of age.
METHODS
Study sites and participants.A longitudinal study, the Schis-
tosomiasis in Mothers and Infants Project, was initiated in
April 2009 to investigate infection dynamics of intestinal
schistosomiasis and malaria in a closed cohort of young
children and their mothers living in six lake shore commu-
nities in Uganda. Three of the study villages (Bugoigo,
Walukuba, and Piida) are located in Buliisa District on
Lake Albert, and three (Bugoto, Bukoba, and Lwanika)
are located in Mayuge District on Lake Victoria.19 The
cohort was followed-up at 3, 6, and 12 months after baseline
and offered treatment. A random sample of children in the
cohort was tested for FOB at baseline. These same children
were retested for FOB if they came to the 6 month and
12 month follow-ups. Only children for whom FOB results
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and S. mansoni egg counts were available for all three time
points were included in the present analysis (n = 382). At
baseline, the mean age of children in this study was 3.0 years
(range = 5 months–5 years) and the male:female ratio
was 1.03.
Questionnaires. Caregivers were interviewed in their local
language and asked a series of questions on behalf of their
children pertaining to health-seeking behavior, current signs
and symptoms, history of previous infections and treatment,
exposure to risk factors for Schistosoma infection, and knowl-
edge of schistosomiasis and soil-transmitted helminths.
Rapid tests and enzyme-linked immunosorbent assays.
Fecal occult blood was detected by using the Instalert OneStep
Fecal Occult Blood Test Devices (Innovacon, Inc., San Diego,
CA) according to the manufacturer’s instructions. In brief,
a specimen collection stick was stabbed into the fecal samples
(first-day fecal samples) at three sites and the small amount of
feces collected was homogenized in extraction buffer. Two drops
of suspension was then applied to the test cassette. Results
were read after five minutes and classified as negative (–),
trace, weak positive (+), medium positive (++), and strong
positive (+++). At each time point, a single urine sample from
each mother and child was tested for schistosomiasis by using
commercially available rapid tests, which detect schistosome
circulating cathodic antigen (CCA; Rapid Medical Diagnos-
tics, Pretoria, South Africa). Finger prick blood (50–100 mL)
was taken from all study participants present at each time
point and hemoglobin levels were measured as described.20
Anemia was defined as a hemoglobin level < 110 g/L and cate-
gorized according to severity as reported.20 The finger prick
blood was allowed to clot and then centrifuged to obtain serum,
whichwas testedon site for antibodies against schistosomiasis by
using a soluble egg antigen enzyme-linked immunosorbent
assay (SEA-ELISA) according to the manufacturer’s instruc-
tions (Scimedx, Denville, NJ).
Parasitologic diagnosis.Microscopic diagnosis of S.mansoni
and geohelminths (Trichuris trichirua, Ascaris lumbricoides,
and hookworm) was conducted in the field on two fecal sam-
ples collected on consecutive days at baseline. Because of
logistic and financial constraints, only one fecal sample was
examined for follow-up surveys, as per World Health Orga-
nization survey guidelines.21 Double Kato-Katz thick smears
(2 + 41.7 mg) were prepared for each sample and inspected
by microscopy at a magnification of 100 +.22 Results were
expressed as mean egg count per gram (epg) of feces. The
S. mansoni and geohelminth infection intensities were clas-
sified as recommended by the World Health Organization.21
To control for potential confounding infections, thick and
thin blood films were prepared for all study participants at
each time point. The slides were stained and malaria para-
sites were counted as described.23
Treatment. At baseline all study participants were treated
with PZQ as described.19 At the 3 month and 6 month follow-
ups, PZQ treatment decisions were based on a positive CCA
test or Kato-Katz result. At 12 months, blanket treatment
with PZQ was provided as an exit strategy for the cohort
children living in Buliisa District. However, cohort children
in Mayuge District were treated on the basis of results of
CCA tests because one additional survey was planned in
this district. At each time point, all study participants were
offered albendazole treatment and persons who were malaria
positive by rapid diagnostic test were offered treatment
with artemether-lumefantrine (20 mg artemether/120 mg
lumefantrine) on an outpatient basis.
Statistical analysis. Data were entered by using EpiData™
(EpiData Association, Odense, Denmark) and converted to
a spreadsheet by using Microsoft (Redmond, WA) Excel 2004
for Mac (version 11.5.6). Statistical analysis was carried out
by using Stata version 9.2 (StatCorp LP, College Station, TX)
andRversion 2.8.1 (http://cran.r.project.org/bin/windows/base/).
Age data were categorized (< 2, 2–4, and > 4 years of age). The
geometric mean of Williams (GMW) and arithmetic mean of
positive samples (AMPOS) were calculated for S.mansoni infec-
tion intensities and 95% confidence intervals (CIs) for GMW
were determined by using the exact method.24 To assess associ-
ations between S. mansoni infection and caregiver-reported
signs/symptoms or FOB, logistic regression was carried out
by using the symptom or FOB as a binary outcome variable
(FOB negative and trace results were classified as negative and
weak-strong positive results classified as positive) and S.mansoni
infection as a categorical explanatory variable. Potential con-
founding variables (including lake, village, age, sex, presence of
other infections, anemia, behavior, and previous treatment) were
introduced into the logistic regressionmodel in stepwisemanner,
and models were compared by using likelihood ratio tests.
Because of small numbers of hookworm-infected persons at
the 6 month and 12 month follow-ups, associations with FOB
were investigated by using the Fisher exact test.25
Diagnostic performance. Sensitivity, specificity, positive
predictive value, and negative predictive value of FOB were
calculated by using S. mansoni infection status (as measured
by the presence of eggs in feces) as a gold standard, and 95%
CIs were estimated by using the binomial exact method.26,27
Receiver operating characteristic analysis was performedusing
the same gold standard and plotting sensitivity against 100 –
specificity to determine the area under the curve (AUC).28 A
number of new variables were generated consisting of FOB
combined with one or more caregiver-reported signs/symptoms
or with anemia. The diagnostic performance of these combined
indicators was determined as described above.
Ethical approval and informed consent. TheLondon School
of Hygiene and Tropical Medicine (LSHTM 5538.09) and the
National Council of Science and Technology, Kampala, Uganda,
granted ethical approval for this study. Informed consent
documented by signature or thumb print was obtained from
each caregiver on behalf of her child or children.
RESULTS
The prevalence of egg-patent S. mansoni infection at base-
line was 20.7% (GMW = 37.7 epg, 95% CI = 26.6–53.6 epg,
AMPOS = 130.2 epg, 95%CI = 76.1–184.2 epg, maximum value
= 1,170 epg). At 6 months, the prevalence was 11.5% (GMW =
69.6 epg, 95%CI = 47.3–102.3 epg, AMPOS = 172.4 epg, 95%CI
= 49.9–294.9 epg, maximumvalue = 2,676 epg) and at 12months
itwas17.8%(GMW= 50.3 epg, 95%CI= 34.6–73.2 epg,AMPOS=
193.8 epg, 95%CI= 94.9–292.7 epg,maximumvalue= 2,556 epg).
In contrast, the prevalence of egg-patent hookworm infection at
baseline was 15.7% (GMW = 61.6 epg, 95% CI = 42.3–89.7 epg,
AMPOS = 167.3 epg, 95% CI = 102.3–232.3 epg, maximum
value = 1,080 epg). At 6 months, the prevalence was 2.1%
(GMW = 118.4 epg, 95% CI = 56.2–249.5 epg, AMPOS = 156.0
epg, 95%CI = 72.1–239.9 epg, maximum value = 288 epg) and at
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12months it was 7.1% (GMW = 111.6 epg, 95%CI= 65.0–191.6
epg, AMPOS = 288.0 epg, 95% CI = 79.3–496.7 epg, maximum
value = 2,760 epg). Only sporadic cases of infection with
A. lumbricoides were detected at any time point, and the
prevalence of T. trichiura infections was low (< 2% at base-
line). The prevalence levels (and 95% CIs) of children
infected with malaria at baseline, 6 months, and 12 months
are summarized in Table 1.
Caregiver-reported signs and symptoms. At baseline, 31.8%
of children were reported to have abdominal pain, 36.6% to
have diarrhea and 11.9% to have visual blood in feces. The
prevalence levels of these caregiver-reported signs and symp-
toms at 6 and 12 months are summarized in Table 1. Although
after controlling for confounding factors there was evidence for
an association between egg-patent S. mansoni infection and
diarrhea at baseline (odds ratio [OR] = 2.9, 95% CI = 1.5–5.6,
P = 0.001), this association was not maintained at 6 month and
12 month follow-ups (Table 2). For reported abdominal pain
and visual blood in feces, there was no obvious positive associa-
tion with S. mansoni infection at any time point, though there
was evidence for an inverse relationship between S. mansoni
infection status and abdominal pain at 12months (Table 2).
Dynamics of Schistosoma mansoni infection and fecal
occult blood. The dynamics of S. mansoni infection as measured
bydifferent diagnostic andmorbiditymarkers is shown inFigure 1.
The prevalence of egg-patent schistosomiasis decreased signif-
icantly between baseline and 6 months, but returned to base-
line levels at the 12 month follow-up. Although there was no
dramatic change in CCA (which infers presence of feeding
worms) over the time course of the study, therewas a substantial
decrease in the prevalence of SEA-ELISA–positive persons
between the 6 and 12 month follow-ups. In contrast, there was
an increase in FOB prevalence between baseline and 6 months,
followed by a significant decrease between 6 months and
12 months (Figure 1A and Table 1). Changes in FOB positiv-
ity over time are shown in Figure 1B, demonstrating that
although only nine children were FOB positive for the whole
year, 45 became positive over the 12 months of the study,
124 had been positive at some point but were negative after
12 months, and 201 were negative for the course of the study.
Of the latter, 25 were egg positive for S. mansoni, most with
light-intensity infections.
Association between fecal occult blood and S. mansoni
infection. Fecal occult blood was strongly associated with
Table 1
Prevalence levels of parasitic infections and morbidity indicators in 382 young children at baseline, 6 months, 12 months*
Organism, factor, or response Intensity of infection or morbidity Baseline (95% CI) 6 months (95% CI) 12 months (95% CI)
Schistosoma mansoni KK Any 20.7 (16.7–25.1) 11.5 (8.4–15.1) 17.8 (14.1–22.0)
Light 15.2 (11.7–19.2) 7.1 (4.7–10.1) 12.8 (9.6–16.6)
Medium 3.7 (2.0–6.1) 3.9 (2.2–6.4) 2.4 (1.1–4.4)
Heavy 1.8 (0.7–3.7) 0.5 (0.06–1.9) 2.6 (1.3–4.8)
S. mansoni CCA Any 17.3 (13.6–21.5) 21.3 (17.3–25.8) 16 (12.5–20.2)
S. mansoni ELISA Any 48.4 (43.3–53.6) 51.6 (46.4–56.7) 35.6 (31.1–41)
Trichuris trichiura Any 1.3 (0.4–3.0) 0.3 (0.007–1.4) 0.3 (0.007–1.4)
Hookworm Any 15.7 (12.2–19.8) 2.1 (0.9–4.1) 7.3 (4.9–10.4)
Light 15.7 (12.2–19.8) 2.1 (0.9–4.1) 7.1 (4.7–10.1)
Medium/heavy 0 0 0.26 (0.007–1.4)
Malaria Any 81.6 (77.2–85.4)† 71.1 (66.3–75.6)‡ 70.2 (65.1–75.0)§
Anemia Any 48.7 (43.6–53.8) 57.2 (52.1–62.2)‡ 49.7 (44.6–54.9)
Mild 25.1 (20.9–29.8) 21.0 (17.0–25.4) 21.5 (17.5–25.9)
Moderate 22.8 (18.7–27.3) 20.5 (16.5–24.9) 26.7 (22.3–31.4)
Severe 3.4 (1.8–5.7) 1.3 (0.4–3.0) 2.1 (0.9–4.1)
FOB Any 20.2 (16.2–24.5) 24.6 (20.4–29.2) 14.9 (11.5–18.9)
+ 11.3 (8.3–14.9) 11.8 (8.7–15.4) 7.1 (4.7–10.1)
++/+++ 8.9 (6.2–12.2) 12.8 (9.6–16.6) 7.9 (5.4–11.0)
Abdominal pain Any 31.8 (27.2–36.8)¶ 32.3 (27.5–37.3)# 69.4 (64.4–74.0)**
Diarrhea Any 36.6 (31.7–41.7)¶ 28.2 (23.7–33.1)# 52.6 (52.6–47.3)**
Blood in feces Any 11.9 (8.8–15.6)¶ 6.2 (4.0–9.1)# 11.1 (8.1–14.8)**
*CI = confidence interval determined using the exact method; KK = Kato-Katz; CCA = circulating cathodic antigen; ELISA = enzyme-linked immunosorbent assay; FOB = fecal occult blood;
+ = weak positive; ++ = medium positive; +++ = strong positive.
†n = 374.
‡n = 381.
§n = 349.
¶n = 377.
#n = 372.
**n = 369.
Table 2
Association between questionnaire responses and Schistosoma mansoni infection in young children at baseline, 6 months, and 12 months*
Questionnaire response
Baseline 6 months 12 months
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Abdominal pain 1.5 (0.8–2.7) 0.17 0.7 (0.3–1.4) 0.32 0.4 (0.2–0.6) < 0.0001
Diarrhea 2.9 (1.5–5.6) < 0.001 0.6 (0.3–1.4) 0.26 0.7 (0.4–1.3) 0.24
Blood in feces 1.4 (0.6–3.1) 0.39 1.2 (0.3–4.1) 0.82 1.3 (0.6–2.9) 0.51
*OR = odds ratio; CI = confidence interval.
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S.mansoni infection at baseline (OR = 3.1, 95% CI = 1.8–5.5,
P < 0.0001), 6 months (OR = 3.4, 95%CI = 1.8–6.5,P < 0.0001),
and 12 months (OR = 3.5, 95%CI = 1.8–6.9, P < 0.0001). At all
three time points, medium and heavy S. mansoni infections
were more strongly associated with FOB than light infections
(Table 3). Controlling for previous treatment with PZQ did
not have any effect on the association between FOB and intes-
tinal schistosomiasis. In contrast, there was no evidence for an
association between FOB and hookworm infection at baseline
(P= 0.49), 6months (P= 0.23), and 12months (P= 0.60).Anemia
was not associated with S. mansoni infection at baseline (OR =
0.8, 95% CI = 0.5–1.3, P = 0.37), 6 months (OR = 1.0, 95% CI =
0.5–1.9, P = 0.96), and 12 months (OR = 0.7, 95% CI = 0.4–1.3,
P = 0.27), and there was also no association between FOB
and anemia at any time point.
The specificity of FOB for predicting egg-patent S. mansoni
infection was 84.2% (95% CI = 79.6–88.1%) at baseline, 78.4%
(95%CI = 73.6–82.7%) at 6 months, and 88.5% (95%CI = 84.5–
91.8%) at 12months. In contrast, the sensitivity was 36.7% (95%
CI = 26.1–48.3%) at baseline, 47.7% (95% CI = 32.5–63.3%) at
6months, and30.9%(95%CI= 20.2–43.3%)at 12months. These
findings are reflected in the results of receiver operating charac-
teristic analysis, which showed AUC values of 0.60 (95% CI =
0.55–0.66) at baseline, 0.63 (95% CI = 0.55–0.71) at six months,
and 0.60 (95% CI = 0.54–0.66) at 12 months (Table 4). Attempts
toenhancediagnostic scoresby combiningFOBwithoneormore
caregiver-reported symptoms or anemia resulted in improve-
ments in specificity but a substantial decrease in sensitivity, and
a reduction in AUC score in comparison with FOB alone
(Supplemental Table 1).
To determine whether FOB prevalence levels changed with
alterations in S. mansoni egg patency over time, FOB preva-
lence levels were stratified on the basis of S. mansoni infection
status at baseline, 6 months, and 12 months (Table 5). Although
the number of persons in most categories was small, there was
an overall tendency for FOB prevalence to decrease as children
became egg negative and increase as children became egg posi-
tive. In children who were egg positive at baseline and egg
negative at 6 and 12 months the reduction in FOB prevalence
between baseline and 6 months was marginal, but was more
substantial 6 months later. In contrast, there was a tendency for
FOB prevalence to increase before egg patency in children who
Figure 1. A, Prevalence levels of fecal occult blood (FOB) and Schistosoma mansoni infection as assessed by Kato-Katz, circulating cathodic
antigen (CCA), and soluble egg antigen–enzyme-linked immunosorbent assay (ELISA) at baseline, 6 months, and 12 months. Error bars represent
95% confidence intervals. B, Dynamics of FOB over the course of the study. + = FOB positive; – = FOB negative; N = no. of children.
Table 3
Association between FOB and Schistosoma mansoni infection in young children at baseline, 6 months, and 12 months*
S. mansoni infection status
Baseline 6 months 12 months
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Negative 1.0 – 1.0 – 1.0 –
Positive 3.1 (1.8–5.5) < 0.0001 3.4 (1.8–6.5) < 0.0001 3.5 (1.8–6.9) < 0.0001
Light infection 1.5 (0.8–3.1) 0.22 2.1 (0.9–4.8) 0.08 2.5 (1.1–5.3) 0.02
Medium or heavy infection 17.0 (6.0–48.6) < 0.0001 7.3 (2.6–20.6) < 0.0001 8.3 (3.1–22.0) < 0.0001
*OR = odds ratio; CI = confidence interval.
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were egg negative at baseline and 6 months but egg positive
at 12months.
DISCUSSION
There is a clear need for field applicable morbidity markers,
particularly in the context of young children and detection of
early stage morbidity.29 In this study, we investigated whether
FOB could be used as a marker to assess bowel morbidity
associated with intestinal schistosomiasis over time and after
PZQ treatment. We have followed-up a cohort of 382 young
children (5 months–5 years of age) in Uganda for one year and
have demonstrated a convincing association between FOB
and S. mansoni infection at baseline, 6 months, and 12 months
set within a context of repeated PZQ and albendazole treat-
ment. In addition, we have found that there was a tendency for
FOB prevalence to increase from baseline to 12 months in
children who become infected with S. mansoni and to decrease
in children who become negative for egg-patent schistosomia-
sis. In contrast, there was no consistent association between
caregiver-reported signs and symptoms (abdominal pain, diar-
rhea, and blood in feces) or anemia (measured by capillary
hemoglobin concentration) and S. mansoni infection over the
duration of the study.
The use of questionnaires enquiring about symptoms, such
as blood in feces and diarrhea, to determine which communi-
ties are at risk for disease has been investigated extensively,
and it is has been shown that self-reported blood in feces is
the symptom most strongly associated with Schistosoma infec-
tion.30 In the present study, we found that only diarrhea, as
reported by the caregiver, was associated with S. mansoni
infection at baseline (i.e., before PZQ treatment). This find-
ing contrasts with those of earlier studies in which blood in
feces and diarrhea were found to correlate with intestinal
schistosomiasis.19 The difference is likely because of a smaller
sample size in the present study; thus, a weak association
might not be detected. Interestingly, there was no consistent
association between any signs and symptoms and S. mansoni
infection over the course of this longitudinal study and treat-
ment. At 12months, there was an inverse relationship between
abdominal pain and S. mansoni infection. The latter observa-
tionmay be caused by other infections, which cause abdominal
pain, but which are either less prevalent or cause less abdomi-
nal pain in children who are positive for S. mansoni. Overall,
these results suggest that self-reporting or caregiver-reporting
of signs and symptoms are not a robust method for monitoring
morbidity after PZQ treatment.
Although we and others have demonstrated an association
between FOB and prevalence or intensity of S. mansoni or
S. japonicum infection,16–19 to our knowledge, this is the first
longitudinal analysis to demonstrate a continued association
between FOB and egg-patent S. mansoni infection after PZQ
treatment. We found that FOB tests were highly specific for
S. mansoni infection at all time points, but not sensitive, indi-
cating that a number of persons with intestinal schistosomiasis
did not show detectable levels of FOB, likely persons with
low infection intensities (Table 3). Thus, FOB tests would not
be appropriate for diagnosis of intestinal schistosomiasis at an
individual or population level, but do have potential for moni-
toring changes in intestinal morbidity associated with schisto-
somiasis at a community level. Consistent with the specificity
of FOB for S. mansoni infection, there was no association
between FOB and hookworm infection. However, it must be
remembered that prevalence level and intensity of this hel-
minth infection were low in the study cohort. In areas where
hookworm prevalence level and intensity are higher, an associ-
ation with FOB may be observed and the specificity of FOB
for S. mansoni infection may be lower.
The potential confounding effects of malaria infections
were controlled for in the analysis and other infections includ-
ing A. lumbricoides, T. trichiura, Strongyloides stercoralis,31
and Entameba histolytica (Betson M, unpublished data) were
at low levels in this cohort. However, we cannot rule out the
presence of additional confounding infectious agents, for
which we did not control. These agents could include bacterial
pathogens such as Shigella or enterohemorrhagic Escherichia
coli and protists such as Giardia. There are few reports on the
population prevalence of such pathogens and their associa-
tions with blood in feces in Uganda. In a cross-sectional sur-
vey of patients who came to health facilities with bloody
diarrhea in Mbarara District, Uganda, Shigella was isolated
from 35% of fecal samples.32 In eastern Kenya, prevalence
levels of Shigella, Campylobacter, and Salmonella in patients
with bloody diarrhea were 44%, 7%, and 3%, respectively.33
Among children with diarrhea in southwestern Uganda, 8%
Table 4
Diagnostic performance of FOB using egg-patent Schistosoma mansoni as a gold standard*
FOB vs. KK and microscopy Baseline 6 months 12 months
Sensitivity (%) 36.7 (26.1–48.3) 47.7 (32.5–63.3) 30.9 (20.2–43.3)
Specificity (%) 84.2 (79.6–88.1) 78.4 (73.6–82.7) 88.5 (84.5–91.8)
PPV (%) 37.7 (26.9–49.4) 22.3 (14.4–32.1) 36.8 (24.4–50.7)
NPV (%) 83.6 (79.0–87.6) 92.0 (88.3–94.9) 85.5 (81.2–89.2)
AUC 0.60 (0.55–0.66) 0.63 (0.55–0.71) 0.60 (0.54–0.66)
*FOB = fecal occult blood; CI = confidence interval; KK = Kato-Katz; PPV = positive predictive value; NPV = negative predictive value; AUC = area under the curve (from receiver operating
characteristic analysis).
Table 5
Prevalence of FOB at baseline, 6 months, and 12 months stratified by
Schistosoma mansoni infection dynamics*
Egg-patent S. mansoni n/N (%)
Baseline 6 months 12 months Baseline 6 month 12 month
− − + 3/29 (10.3) 12/29 (41.4) 8/29 (27.6)
– + + 1/2 (50.0) 2/2 (100) 0/2 (0)
− + – 0/8 (0) 0/8 (0) 2/8 (25.0)
+ − − 11/29 (37.9) 9/29 (31.0) 4/29 (13.8)
+ + – 4/13 (30.8) 9/13 (69.2) 3/13 (23.1)
+ – + 2/16 (12.5) 4/16 (25.0) 4/16 (25.0)
+ + + 12/21 (57.1) 10/21 (47.6) 9/21 (42.9)
− − − 44/264 (16.7) 48/264 (18.2) 27/264 (10.2)
*FOB = fecal occult blood.
698 BETSON AND OTHERS
were infected with Shiga toxin–producing E. coli (STEC).34 In
contrast, no Shiga toxin–producing E. coli was found among
infants with diarrhea in Kampala.35 Low prevalence levels of
Giardia lambia andE. histolyticawere found among school chil-
dren inKampala,36 whereas in westernUganda, 41%of persons
were infected with Giardia, but no association was found
between Giardia infection and gastrointestinal symptoms.37
To date, no studies on these pathogens and associations with
blood in feces or FOB have been carried out in the areas where
our study was conducted. Such bacterial or protist infections
may account for fecal occult blood at baseline in 48 children
who were negative for S. mansoni infection by microscopy.
However, 22 (46%) of these children were positive by SEA-
ELISA, and 3 (7%) of 45 were positive for CCA, highlight-
ing the diagnostic insensitivity of the Kato-Katz test and
suggesting that these children may have eggs trapped in their
intestinal mucosa even if they are not detectable in their feces.
Although we were not able to demonstrate a significant
reduction in the prevalence of FOB over a 12-month period,
this finding was likely caused by the fact that there was also
no significant reduction in overall prevalence and intensity of
egg-patent S. mansoni infection in this cohort over the duration
of the study. Intriguingly, however, there was a reduction in
the number of SEA-ELISA–positive persons between 6 and
12 months, suggesting a reduction in the accumulation rate of
eggs or a dampening of the immune response, perhaps immuno-
tolerance in the younger child.
When FOB results were stratified by S. mansoni infection
status at baseline, 6 months, and 12 months, we did observe a
reduction in FOB prevalence in children who became negative
for egg-patent S. mansoni (and the reverse in those children
who became egg patent). Although the number of persons in
each category was small, there was some indication that there
may be a lag between becoming egg negative and a reduction
in FOB. For example, in childrenwhowere S.mansoni positive
at baseline but then negative at 6 months and 12 months, there
was a small reduction in FOB prevalence at 6 months but by
12 months FOB prevalence was at background levels. This
finding suggests that it may take up to 12 months for the gut to
heal properly, perhaps because of polyps in the intestinal
mucosa that take time to resolve or ongoing inflammatory
responses to trapped and dying eggs. Interestingly, in children
who were egg negative at baseline and 6 months but egg posi-
tive at 12 months, there was also some suggestion that they
became FOB positive before they were egg patent. At six
months, eight (67%) of these FOB-positive children were pos-
itive by SEA-ELISA, suggesting that S. mansoni eggs were
already present in their gut lining. Thus, FOB may be able to
detect early stages of bowel pathologic changes even before
infections are detectable by microscopy. This finding is consis-
tent with previous work demonstrating that first S. mansoni
infections in young children are detected earlier by SEA-
ELISA than bymicroscopy.38
Of particular note is that our cohort consisted of young
children, who likely present an early stage of pathologic
changes associated with intestinal schistosomiasis and in
whom the bowel is continuing to develop and mature. It is
important to note that despite their young age, 21%of children
were egg patent at the start of the study and 20%demonstrated
bowel morbidity as detected by the FOB test. These data add
to the mounting evidence that young children are at risk of
S. mansoni infection and demonstrate overt schistosomiasis-
associated morbidity.13,14 Fecal occult blood may prove a
highly appropriate intestinal morbidity marker for persons
such as young children who have acquired their infections
recently because they may show greater intestinal bleeding
than long-standing infections, perhaps a consequence of the
fact that there is a reduction in the immune response to schis-
tosomiasis over time and also variation in the numbers of eggs
produced by adult worms against a background of preventive
chemotherapy.39 Interestingly, previous treatment did not
have an effect on the association between FOB and S. mansoni
infection, suggesting that over the time course of this study,
treatment with PZQ did not reduce intestinal morbidity on
subsequent re-infection.
In conclusion, we have shown in a cohort of young children
in Uganda that FOB continues to be strongly associated with
the prevalence and intensity of S. mansoni infection over a
period of one year and after repeated PZQ and albendazole
treatment, unlike self-reported symptoms and anemia. Thus,
we propose that this rapid test could be useful for control pro-
grams to evaluate the extent and dynamics of intestinal mor-
bidity in young children at a community level and to monitor
changes in morbidity after mass chemotherapy.
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